Abstract

Gastrointestinal bleeding (GIB) is one of the major complications among the patient who are on anticoagulation. Non‐vitamin K antagonist oral anticoagulants (NOACs) are with haemorrhage-linked and included significant or minor gastrointestinal tract bleeding, intracranial haemorrhage and bleeding from oral cavity. The current study was aimed at evaluation of GIB hazard with (NOACs) specially rivaroxaban. 150 patients were taken to participate in this study. This study analysis showed that rivaroxaban was not associated with a significantly GIB, intracranial bleeding and oral bleed. Patients presented with GIB and oral bleed were 19% and 15% respectively. Only 7% patients were presented with intracranial bleed. However, the result was not statistically significant. The attached hazard of major GIB lacked divergence between NOACs and vitamin K antagonists (VKA) among patients who were diagnosed with atrial fibrillation (AF) and venous thromboembolism (VTE). The current study establishes that, regardless of any preceding information that may back any affiliation of GOIB, NOAC and NOVAC, they remain unaffiliated with enhanced hazard of major GIB when matched with a different anticoagulant therapy.

Key Words: Venous thromboembolism (VTE), vitamin K antagonist oral anticoagulants (NOACs), Gastrointestinal bleeding (GIB).